Company* (Country; Symbol)

University/
Non-Profit

Type Of
Agreement

Product Area

Details (Date)


3rd Millennium Inc.*

Department
of Defense

Phase I SBIR contract

To develop a bioinformatics system for the management and analysis of microarray data

The work is supported by the U.S. Army Medical Research and Material Command; the system will advance the DOD's plan in infectious diseases (2/13)

Acambis plc
(UK; LSE:ACM)

U.S. government

Contract

To manufacture and deliver 155M doses of smallpox vaccine within the next 12 months

The agreement is worth $428M to Acambis (12/5**)

Aclara BioSciences
Inc.
(ACLA)

Stanford University School of Medicine

Collaboration

To apply Aclara's eTag technology for proteomics research

The Stanford researchers plan to characterize serum autoantibody profiles in a variety of autoimmune diseases to develop immunology proteome panels for use in drug discovery, clinical medicine and academic research (1/17)

Active Pass Pharmaceuticals Inc. (Canada)*

Baylor College of Medicine

Licensing agreement

ABCA4 gene, also known as ABCR, implicated in age-related macular degeneration

Active Pass licensed the rights to the gene (1/3)

Adprotech Ltd. (UK)*

UK Medical Research Council

Licensing agreement

To exploit two MRC patents related to MSP1.19

The MRC receives an up-front payment, annual fees, milestone payments and royalties on vaccines (1/23)

Agencourt Bioscience
Corp.*

National Institutes
of Health

Agreement

For Agencourt to provide genomic services to the NIH's Mammalian Gene Collection project

Agencourt will use its Solid Phase Reversible Immobilization technology to sequence tag mammalian cDNAs as part of the MGC goal to identify and accurately sequence full-length cDNAs (1/22)

AgraQuest
Inc.*

University of California at San Diego

Research agreement

To investigate deep marine sediment microbes for use as biological pest management solutions for controlling fungal disease, insects and nematodes

The research will be carried out in collaboration with the laboratory of William Fenical, from the Scripps Institution of Oceanography, UCSD (2/8)

Albany Molecular Research Inc.
(AMRI)

National Cancer Institute

Cooperative research and development agreement

To develop anticancer compounds

AMRI will prepare derivatives of lead compounds to identify new analogues that maintain promising anticancer activity (12/14)

Alfacell Corp.
(OTC BB:
ACEL)

Martin Michaelis at the Institute of Medicinal Virology at Johann Wolfgang University

Collaboration

Focused on the use of Onconase, an anticancer drug to treat various forms of childhood soft tissue and muscle cancer

Results of in vitro studies show antitumor activity of Onconase against neuroblastoma, rhabdomyosarcoma and chemotherapy-resistant variants of the same cell lines (1/29)

Ambion Inc.*

Massachusetts Institute of Technology

Licensing
agreement

For patent applications covering small interfering RNA

Financial details were not disclosed (3/11)

AMDL Inc.
(AMDL)

Lung-Ji Chang
at the University
of Florida

Study
agreement

To develop a targeted immunogene therapy for breast cancer

The technology will be tested in a breast cancer mouse model (1/9)

American
Biogenetic
Sciences Inc.
(MABA)

Russian
associations

Ten-year agreements

To give ABS exclusive rights to distribute in specified markets Russian-manufactured anthrax and smallpox vaccines

One agreement gives ABS the exclusive right to sell and distribute worldwide an anthrax vaccine produced by a Russian manufacturer (1/22)

Amersham
Biosciences

(unit of Amersham plc; UK; NYSE:AHM)

University of Washington

Proteomics collaboration

To integrate protein and messenger RNA expression data

The RNA expression data will be generated using Amersham's Two-Dimensional Differential In-Gel Electrophoresis technology and DNA microarray platform (3/11)

Antex Biologics
Inc.
(AMEX:ANX)

Walter Reed Army Institute for Research

Extended product development agreement

To manufacture clinical trial materials

The materials include seed banks and Phase I clinical trial material for the Tracvax vaccine against Chlamydia trachomatis (1/15)

Applied
Biosystems
(NYSE:ABI)

Vanderbilt
University

Collaboration
agreement

For technologies and applications for proteomics and small-molecule analysis

The parties will use a new direct molecular imaging technique and approach to analyze tissue (2/12)

Applied Genetic
Technologies
Corp.*

Johns Hopkins
University

License
agreement

For use of adeno- associated virus gene therapy vectors in muscle tissue

AGTC gains the right to develop the AAV technology for injection into human muscle tissue for potential therapy of alpha-1 antitrypsin deficiency and Pompe's disease (2/20)

Atugen AG
(Germany)*

University of California at San Francisco

Validation
agreement

To validate the function of genetic targets

Atugen USA Inc., a subsidiary of Atugen, will develop GeneBlocs to evaluate in Madin-Darby canine kidney cells genetic targets associated with epithelial membrane regulation; Atugen will get the first option to commercialize resulting technology (1/23)

AVI BioPharma
Inc.
(AVII)

Oregon State University in Corvallis

Licensing agreement

For a patent titled, “Calcivirus Infections in Humans: Diagnosis and Prevention"

Terms were not disclosed (2/12)

AxCell Biosciences
Corp.
(subsidiary of Cytogen Corp.; CYTO)

Marius Sudol of the Mount Sinai School of Medicine

Research collaboration

To research protein interactions in the WW protein domain family, believed to play a role in muscular dystrophy and neurodegenerative diseases, such as Alzheimer's disease

AxCell has an option to negotiate an exclusive, worldwide, royalty-bearing license from the school for peptide targets, gene targets and any other inventions that result (3/11)

AxCell Biosciences
Corp.
(subsidiary of Cytogen Corp.; CYTO)

Thomas Jefferson University

Research agreement

For protein interactions associated with an undisclosed gene believed to play a role as a tumor suppressor in multiple cancers

Intellectual property derived from the collaboration will be jointly owned, with AxCell retaining an option to negotiate an exclusive worldwide royalty-bearing license for any joint intellectual property (3/6)

BD Biosciences
(unit of Becton,
Dickinson and Co.; NYSE:BDX)

Harvard Institute
of Proteomics at Harvard Medical School

Collaboration

To generate thousands of gene clones involved in biological processes

Harvard scientists will use the BD Creator gene cloning and expression system to clone the genes; BD Biosciences will retain commercial rights to the resulting cloned genes and will support the proteomics program (1/29)

Bioject Medical
Technologies
Inc.
(BJCT)

Memorial-Sloan Kettering Cancer Center

Agreement

To study the efficacy of the Biojector 2000 on immune responses to DNA vaccines

The studies will seek to determine the cellular and molecular mechanisms responsible for the enhancement of immunogenicity associated with needle-free injection (1/18)

BioMicro Systems
Inc.*

National Cancer Institute, the Huntsman Cancer Institute and the Buck Institute for Age Research

Agreement

To evaluate its Microarray User Interface hybridization product

The alpha sites will test BioMicro's MAUI microfluid analysis product used to expedite the drug discovery process by obtaining results from microarray hybridization (2/20)

BSKB Medical
Ventures LLC*

California State University, Fullerton

Licensing agreement

To commercialize a technology relating to a new class of potential antibodies

The company formed Pyro Pharmaceuticals Inc. to exploit the technology, which focuses on a metabolic pathway required for bacterial viability (2/6)

Caprion
Pharmaceuticals
Inc.
(Canada)*

McGill University

Collaborative agreement

To expand Caprion's proteomics research

Caprion will provide McGill financial support; Caprion will have access to certain intellectual property developed under the collaboration, and will have exclusive rights to license any proteomic technologies developed; the funding could exceed $1M in the next five years (2/27)

Carrington
Laboratories
Inc.
(CARN)

Southern Research Institute

Partnership

To assist in the commercialization of Carrington's drug delivery technology based on the natural polymer CR1013

Carrington will retain all product rights plus intellectual property rights to its existing technology, as well as to any discoveries made (1/24)

Celera
Genomics
Group
(NYSE: CRA)

Institute for OneWorld Health and the National Institutes of Health

Development agreement

For CRA-3316 as a potential new treatment for Chagas' disease

Celera gave IOWH the exclusive license to develop CRA-3316 for parasitic infections in humans (2/14)

Celera
Genomics
Group
(NYSE: CRA)

UK Medical Research Council

Multiyear agreement

For access to Celera's database products

The agreement is open to all UK-based academic researchers (2/1)

Ciphergen
Biosystems Inc.
(CIPH)

Aaron Diamond AIDS Research Center

Research and license agreement

To pursue projects related to discoveries and samples provided by the center, as well as joint discoveries

Ciphergen retains therapeutic and diagnostic rights to discoveries made under the collaboration, with royalties paid back to Aaron Diamond (2/14)

Ciphergen
Biosystems Inc.
(CIPH)

Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases

Collaborative research and development agreement

To discover CD8+ T cell-derived antiviral factors

The parties will use Ciphergen's ProteinChip Biomarker System (2/14)

Co.don AG
(Germany)*

Massachusetts Institute of Technology and Tufts University

Collaboration

Basic research on tissue engineering

The research is aimed at improving tissue grafts (2/13**)

Collateral
Therapeutics
Inc.
(CLTX)

University of Texas Southwestern Medical Center at Dallas

Option
agreement

To license exclusive worldwide gene therapy rights

Collateral will evaluate the development and potential commercialization of EPAS1 in its ongoing nonsurgical cardiovascular gene therapy programs (3/13)

Conforma
Therapeutics
Corp.*

Duke University Medical Center

Exclusive licensing agreement and research collaboration

Screening technology, X-ray crystal structure information and a proprietary target for drug discovery

Conforma also initiated a research collaboration with a Duke associate professor that gives Conforma a five-year exclusive option to license all inventions that result from the research (12/6)

Cytomyx plc (UK;AIM:CYX)

Papworth
Hospital NHS
Trust

Collaboration

To discover and validate new targets associated with cardiovascular disease

The initial focus will be dilated cardiomyopathy, a disease of the heart muscle; Papworth will receive royalties on products generated through the collaboration (1/16)

Deltagen Inc.
(DGEN)

Stanford
University

Three-year target validation and research collaboration agreement

To develop research projects for jointly selected genes under which Deltagen will provide Stanford nonexclusive access to knockout mice models using its high-throughput technology

Deltagen will have options to obtain exclusive licenses to commercially develop certain inventions developed by Stanford; Deltagen will have rights to use, commercialize and sublicense resulting products (2/19)

DyoDelta
Biosciences
Ltd.
(UK)*

University of
Patras

Licensing
agreement

For a pharmaceutical compound program developed by the university's John Matsoukas

DyoDelta exclusively licensed DDB-202 for the therapeutic management of multiple sclerosis (3/19)

Endovasc Ltd. Inc. (OTC BB:ENDV)

Stanford
University

Option
agreement

To acquire an exclusive, worldwide patent license for the use of nicotine in stem cell and progenitor cell recruitment focused in the areas of cardiology and neurology

The patent is titled, "Nicotine Receptor Agonists in Stem Cell and Progenitor Cell Recruitment“ (2/4)

Entelos Inc.*

American
Diabetes
Association

Collaboration and research agreement

For drug discovery and development to treat Type II diabetes

The parties will generate novel theories, hypotheses and discoveries relating to Type II diabetes (3/11)

EraGen
Biosciences
Inc.*

McGill
University

Research
agreement

To design universal DNA microarrays using proprietary Aegis technology

The project will produce universal arrays that are not specific to a single organism or set of genes and will allow for simultaneous monitoring of multiple hybridizations (12/5)

Exact Sciences
Corp.
(EXAS)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University

Collaboration

To develop a novel technology to analyze DNA extracted from stool samples

The technology is known as digital protein truncation (1/30)

Fujirebio
Diagnostics Inc.*

Yale University

Development and commercialization agreement

For cancer diagnostic tests based on the cancer-specific gene Survivin

Fujirebio acquired the rights; agreement also includes diagnostic rights for therapeutic drug monitoring; Fujirebio will provide Yale with license fees, milestone payments and royalties (3/5)

Genentech Inc.
(NYSE:DNA)

Accelerate Brain Cancer Cure (ABC[2])

Collaboration

To develop new therapies designed to treat patients with brain cancer

ABC(2) will share development expenses and provide access to its resources; Genentech will design and develop the therapeutics; Genentech will commercialize any resulting products and ABC(2) will receive a royalty on product sales (2/25)

Genome Prairie
(Canada)*

Agriculture and Agri-Food Canada research facilities and the National Research Council Plant Biotechnology Institute

Research
agreement

To work with wheat and canola, examining the whole plant and studying the crops at the molecular level

The study may lead to the development of plants with improved stress-resistance properties; the research agreement is worth $19.3M (3/1)

GenVec Inc.
(GNVC)

National Institutes
of Health

Letter contract

To develop and manufacture preventative AIDS vaccines

The agreement could mean up to $10M over three years for GenVec (1/10)

GenVec Inc.
(GNVC)

Vaccine Research Center at the National Institute of Allergy and Infectious Diseases

Contract
agreement

To use GenVec's adenovector technology to develop and manufacture clinical- grade preventive AIDS vaccine candidates

GenVec also will work on developing an advanced, scaleable vaccine production process using manufacturing technologies developed at GenVec and designed to support product commercialization (2/5)

Hollis-Eden
Pharmaceuticals
Inc.
(HEPH)

Uniformed Services University of the Health Sciences and the Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.

Cooperative research and development agreement

To develop HE2100 for use in the area of radiation protection

Hollis-Eden retains all rights to HE2100, including rights to supply it to the U.S. government (2/14)

Hybridon Inc.
(OTC BB:HYBN)

Duke University

Collaboration

To develop Hybridon's class of immunomodulatory oligonucleotides

In coordination with the agreement, Hybridon added a senior scientific adviser, David Pisetsky (1/3)

IGEN
International
Inc.
(IGEN)

U.S. Army Space and Missile Defense Command

Agreement

To sell products to the Army based on IGEN's Origen technology for the detection of specific biological agents

IGEN received and filled an order for 20 Origen analyzers for delivery to the Department of Defense; revenues are expected to be at least $2M (3/13)

Illumina Inc.
(ILMN)

Boston University Medical Center

Commercial
agreement

To provide single nucleotide polymorphism genotyping services for a large-scale research project on preterm birth

Illumina will use its BeadArray technology to score a set of SNPs thought to be associated with preterm birth (1/29)

Illumina Inc.
(ILMN)

Johns Hopkins University, Institute of Genetic Medicine

Commercial
agreement

To provide single nucleotide polymorphism genotyping services on a sample collection

Illumina will use its BeadArray technology to determine the frequency of specified SNPs in the sample set; Illumina also will design functional assays for most of the SNP loci provided by the institute (1/9)

Immune Network
Ltd.
(Canada)*

Brian Conway of the University of British Columbia

Research
agreement

To develop treatment of HIV and hepatitis C virus

The agreement is primarily to learn more about 1F7, an antiidiotypic immunomodulatory monoclonal antibody, as a potential treatment for HIV and HCV (1/22)

InforMax Inc.
(INMX)

State University of New York at Buffalo

License
agreement

For the GenoMax enterprise bioinformatics system and Vector NTI Suite

The software solutions will be used to support research activities and provide statwide academic access to InforMax's bioinformatics products (3/6)

Interleukin
Genetics Inc.
(ILGN)

University of Arkansas for Medical Sciences, College of Medicine

Collaboration

On the genetic causes of inflammation in relation to Alzheimer's disease and to identify drug targets

Interleukin Genetics will provide gene variations and cell lines while UAMS provides technical knowledge in gene expression and models of Alzheimer's disease (3/4)

Intradigm
Corp.*

University of Maryland at Baltimore

Exclusive access agreement

To patented technologies that include gene delivery polymers and all applications of synthetic vectors to cancer gene therapies that inhibit tumor angiogenesis

Intradigm said it will use the technologies to support its business activities in the discovery and validation of gene function directly in animal models and in development of delivery methods for gene therapies (2/1)

Kourion
Therapeutics
(Germany)*

Case Western Reserve University

Collaboration

To study the differentiation potential of a type of stem cell obtained by Kourion

A possible application might be the repair and healing of complicated bone fractures; the collaboration is with the university and its researcher, Arnold Caplan (12/20)

Lynx
Therapeutics
Inc.
(LYNX)

Dana-Farber Cancer Institute

Collaboration

AIDS research

Parties have the goal of identifying cellular targets for diagnostics and therapeutics for HIV-1 infection (1/3)

Microbiotix Inc.*

Wayne State University and the University of Michigan

Licensing agreement

To a series of antiviral compounds

The compounds discovered through the research efforts of Jiri Zemlicka and John Drach demonstrated activity against a variety of disease-causing viruses, including cytomegalovirus, hepatitis B and Epstein-Barr (12/11)

MitoKor Inc.*

Buck Institute for Age Research and the University of Oregon

Research collaboration and technology transfer and option agreement

To decipher the human mitochondrial proteome

Mitochondrial dysfunction is a major contributing factor in the pathophysiology of major diseases such as Alzheimer's and Parkinson's diseases and Type II diabetes (1/16)

Morewood
Molecular
Sciences
Inc.*

Harvard
University

Nonexclusive license

Morewood's technology for ultra-fast enzymatics

The technology involves a high-throughput screening method of certain molecules for specific biological effects (2/11)

Morphotek Inc.*

The Wistar
Institute

Research and development agreement

To develop improved monoclonal antibodies

Morphotek will apply its Morphodoma technology to Wistar Hybridoma cell lines in order to create second- generation hybridomas that produce monoclonal antibodies for the diagnosis and treatment of cancer and other diseases; Wistar and Morphotek will jointly own the second- generation hybridomas (2/6)

Neoprobe Corp.
(OTC BB:NEOP)

University of California at San Diego

Exclusive license agreement

For the rights to a compound developed by researchers at UCSD

Lymphoseek is the compound being researched for its effectiveness in identifying lymphatic tissue in breast and melanoma cancer patients (2/4)

Neurogenetics
Inc.*

University of California at Irvine

Research initiative

To research the characterization of a novel target recently linked to Alzheimer's disease

The research is funded in part by a BioStar award (1/28)

NovaRx Corp.*

Hoag Cancer Center

Collaboration

To conduct a Phase II trial using an experimental cancer vaccine in patients with lung cancer

The vaccine is made of nonsmall-cell lung cancer cell lines that have been genetically modified through growth factor-beta antisense (2/4)

Novavax Inc.
(NVAX)

Stroke branch of the National Institute of Neurological Disorders and Stroke

Cooperative research and development agreement

E-selectin anti-stroke project

The agreement will test whether repeated administration of low-dose, intranasal E-selectin can induce mucosal tolerance to the protein, causing a shift of immune responses, such that delayed type hypersensitivity is suppressed and the numbers of lymphocytes that produce the anti-inflammatory cytokine is increased (12/19)

Oxford Natural
Products plc

(UK)*

Center for Research and Development of Ethnomedicinal Plants (Vietnam)

Agreement

For access to a portfolio of plant medicines

The portfolio includes materials with well-documented anticholesterol and hepato-protective functions (1/30**)

Paradigm
Genetics Inc.
(PDGM)

Duke University Medical Center

Multiyear collaborative research agreement

To apply metabolomics in drug discovery and development

Paradigm and Duke will research multiple disease areas to identify and validate novel drug targets for drug discovery, as well as discover new biomarkers for use in predictive medicine; cardiovascular disease will be the first project (2/25)

Protein Sciences
Corp.*

National Institute
of Allergy and Infectious Diseases

Contract

The development and production of antigens for new vaccines for HIV/ AIDS

The contract provides for up to $76M in funding through mid-2006 (12/12)

Proteome Systems
Ltd.
(Australia)*

Cystic Fibrosis Foundation Therapeutics Inc.

Collaboration

On a proteomics research program to discover protein targets for cystic fibrosis

The proteins may be used to monitor the progression of the disease and lead to more effective intervention strategies, or as potential targets for the development of new drugs (3/19)

Pyrosequencing
AB
(Sweden; SSE:PYRO)

University of California at San Francisco

Research
agreement

To analyze genes involved in the development and potential progression of multiple sclerosis

Researchers will use Pyrosequencing's PSQ 96 System and analyze the genotypes of about 2,500 patients, their affected siblings and unaffected family members (12/6)

Quatrx Pharma-
ceuticals
Co.*

Temple
University

Exclusive worldwide agreement

For an intranasal delivery technology

Quatrx's vitamin D analogue technology platform will be developed for a variety of indications, the first being the topical treatment of psoriasis (1/23)

Quatrx Pharma-
ceuticals
Co.*

Wisconsin Alumni Research Foundation at the University of Wisconsin and Deltanoid Inc.

Exclusive worldwide development and marketing agreement

For the topical use of vitamin D analogues

No further details were disclosed (1/23)

Rigel Pharma-
ceuticals
Inc.
(RIGL)

Pennsylvania State University and Oklahoma Medical Research Foundation

Agreements for intellectual property

Siclopps technology and the patent estate to the RBX, or ROC1, protein

Rigel in-licensed Siclopps from Penn State; Siclopps will help the company to develop intra-cellular cyclic peptide libraries; Rigel also in-licensed the patent estate from Oklahoma Medical; the protein is a ubiquitin ligase target with potential therapeutic importance in oncology and inflammatory disease (2/21)

Silico Insights
Inc.*

Huntsman Cancer Institute at the University of Utah

Collaboration

To develop a better understanding of cancer mechanisms leading to diagnostic and drug development targets

The agreement will use data resources available at the university to study genealogically related families in clinical settings for the diagnosis and treatment of cancer; the initial focus will be on melanoma (3/11)

SonoLight Pharmaceuticals Corp. (unit of Altachem Pharma Ltd.; Canada; CDNX:AAF)

The Institutes of Chemistry and Biophysics, Acadamia Sinica of Beijing

Exclusive licensing and product development agreement

Technology related to hypocrellins and their derivatives

Financial details were not disclosed (1/8)

Transgenomic
Inc.
(TBIO)

Max Planck Institute for Molecular Genetics

Multiyear collaboration

To develop a high-throughput genetic variation discovery system

The collaboration is funded by the German National Genome Research Network (2/7)

U.S. Genomics
Inc.*

Pui-Yan Kwok, a researcher at Washington University School of Medicine

Research collaboration

Focused on genetics and technology

Kwok's laboratory will employ U.S. Genomics' direct, linear DNA analysis technology for multiple applications; Kwok also will work to extend the development of the technology platform toward additional applications in the field of genetics (2/20)

U.S. Genomics
Inc.*

The Wellcome Trust Sanger Institute

Collaboration

To examine the use of U.S. Genomics' direct, linear DNA analysis technology in research on the human genome

The parties will use the Gene-Engine technology and other aspects of U.S. Genomics' technology platform (1/28)

Xencor Inc.*

California Institute of Technology and Pennsylvania State University

Licensing
agreements

To further expand its protein design automation platform

The agreements expand the patent estate of the PDA technology and increase Xencor's computational throughput and accuracy in protein optimization (2/20)

Xencor Inc.*

Johns Hopkins University School of Medicine

Licensing
agreement

For U.S. Patent No. 6,190,856 B1 titled, "Methods of Detection Utilizing Modified Bacteriophage“

The license will expand Xencor's patent estate for its chemical genomics platform, ProCode (3/11)

Xencor Inc.*

Torrey Mesa Research Institute

Discovery
agreement

To focus on the discovery of proteins for products in the food, pharmaceutical and personal care industries

Xencor will receive research support, potential milestone payments and royalties on products (1/3)

Xeotron Corp.*

U.S. Navy, Office
of Special Technology

Development
agreement

To develop technology for a Microfluidic Array Parallel Synthesis System for production of multistrands of oligonucleotides for use in assembling long DNA sequences

The process, based on Xeotron's technology platform, is designed to accelerate production of oligonucleotides with reduced cost; the contract is worth $3M (2/4)

Zetiq
Technologies
Ltd.
(Israel)*

Karolinska
Institute
(Sweden)

Research
collaboration

To identify new tumor suppressor genes, which provide protection against unrestricted cell proliferation

Zetiq will use its CamaRx technology platform to screen a large number of putative tumor suppressor genes being studied at the institute (3/19)


Notes:

This chart does not include grant agreements (unless they are also part of a larger collaboration) or agreements between biotech companies and clinical trial centers.

* Denotes privately held company.

** Denotes the date the item ran in BioWorld International.

Unless otherwise noted, shares are traded on the Nasdaq exchange.

AIM = Alternative Investment Market of the London Stock Exchange; AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over the Counter Bulletin Board; SSE = Stockholm Stock Exchange